Showing papers by "Garth J. S. Cooper published in 1991"
TL;DR: It is concluded that insulin and amylin are co-secreted from islet beta-cells, and HIT cell line is a useful model in which to studyAmylin metabolism.
160 citations
TL;DR: It is reported that amylin caused a dose‐dependent increase in activity of muscle glycogen phosphorylase in isolated rat soleus muscle by stimulating phosphory lase a, which could be a major mechanism whereby amyl in modulates carbohydrate metabolism.
67 citations
TL;DR: Results fit with a scheme in which amylin elicits muscle glycogenolysis, release of lactate, and increased hepatic gluconeogenesis due to increased supply of substrate.
65 citations
TL;DR: These studies provide the first evidence that there is a mechanism within the pancreas whereby independent secretion of amylin and insulin can occur and the molar ratio ofAmylin to insulin secreted from both normal and diabetic pancreases can vary over a wide range.
55 citations
TL;DR: It is reported that 8–37hCGRP antagonizes amylin inhibition of insulin‐stimulated labelled glucose uptake into isolated rat soleus muscle, and inhibits amyl in‐evoked elevation of plasma lactate and glucose in fasted anaesthetized rats.
49 citations
Patent•
10 Jun 1991TL;DR: The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive as mentioned in this paper. But the present invention is not related to the present paper.
Abstract: The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.
47 citations
TL;DR: It is shown that peroxovanadates are useful and important agents for investigating the mechanism of action of insulin in skeletal muscle and are maximally stimulated the rate of glycogen synthesis in incubated soleus muscles isolated from Wistar rats.
Abstract: 1. The insulin-like effects of orthovanadate (10 mM) and peroxides of vanadate (peroxovanadates, at 1 mM) on rates of lactate formation, glucose oxidation and glycogen synthesis were measured in incubated soleus-muscle preparations isolated from non-obese Wistar rats and lean (fa/?) or insulin-resistant obese Zucker (fa/fa) rats. 2. The stimulation of the rates of lactate formation and glucose oxidation by either orthovanadate or peroxovanadates was of similar magnitude to the stimulation by a maximally effective concentration of insulin (1000 microunits/ml). 3. Peroxovanadates, but not orthovanadate, maximally stimulated the rate of glycogen synthesis in incubated soleus muscles isolated from Wistar rats. 4. When soleus-muscle preparations were incubated in the presence of both insulin (1000 microunits/ml) and peroxovanadates (1 mM), this did not result in a synergistic increase in the rate of total glucose utilization as compared with either agent alone. 5. Soleus muscles isolated from obese (fa/fa) Zucker rats exhibited a decrease in response to a physiologically relevant concentration of insulin (100 microunits/ml). Peroxovanadates, at 1 mM, maximally stimulated the rate of glycogen synthesis in soleus muscles isolated from obese (fa/fa) Zucker rats. 6. The findings indicate that peroxovanadates are useful and important agents for investigating the mechanism of action of insulin in skeletal muscle.
36 citations
TL;DR: In streptozotocin‐diabetic rats treated with insulin replacement, liver glycogen is some 35% depleted, and five consecutive daily subcutaneous injections with amylin dose‐dependently restored liver glucose levels to normal levels.
29 citations
TL;DR: It is proposed that amylin lack plays a significant role to promote the tendency to hypoglycemia and defective glycemic control characteristic of insulin-treated patients with autoimmune diabetes.
26 citations
Journal Article•
1 citations
Patent•
14 Aug 1991
TL;DR: In this paper, the authors traite le diabete sucre non-insulin-dependent or type 2, en administrant un agent hypoglycemique, which stimule les concentrations d'amyline dans le plasma and un antagoniste, which peut etre a sulfonyluree ou un biguanide.
Abstract: On traite le diabete sucre non insulinodependant ou de type 2, en administrant un agent hypoglycemique qui stimule les concentrations d'amyline dans le plasma et un antagoniste d'amyline. L'agent hypoglycemique peut etre une sulfonyluree ou un biguanide. L'antagoniste d'amyline peut etre un peptide d'amyline ou un peptide apparente a un gene de calcitonine qui a des sites reactifs alteres, qui est reticule ou tronque. En outre, on surveille les patients pour detecter l'augmentation des concentrations d'amyline dans le plasma, suite a l'administration des agents hypoglycemiques, et les effets des agents sur la secretion d'amyline dans un systeme biologique tel qu'une culture cellulaire d'un ilot de cellules beta sont surveilles au moyen d'une analyse.